Development
e-therapeutics plc
ETXPF
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -3.66% | -27.03% | -4.59% | -10.17% | 7.29% |
| Total Depreciation and Amortization | 3.62% | 21.50% | 4.60% | -12.08% | -7.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.65% | -709.55% | 4.51% | 137.69% | 7.28% |
| Change in Net Operating Assets | -3.64% | -133.37% | 4.58% | 212.57% | 7.27% |
| Cash from Operations | -3.66% | -113.58% | -4.59% | 35.18% | 7.29% |
| Capital Expenditure | -3.23% | 69.90% | -5.10% | 68.59% | 7.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.68% | -36.05% | 4.59% | -97.65% | -7.29% |
| Cash from Investing | 3.69% | -34.46% | 4.62% | -97.75% | -7.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 46.29% | 0.00% | -- | -- |
| Issuance of Common Stock | 0.00% | -99.84% | 0.00% | 167,762.50% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -3.66% | -101.46% | 4.59% | 153,300.00% | -7.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.66% | -168.47% | 4.59% | -6.68% | -7.29% |